Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Drug-drug Interaction Study With ASP1941 and Glimepiride

This study has been completed.
Information provided by:
Astellas Pharma Inc Identifier:
First received: February 21, 2011
Last updated: NA
Last verified: February 2011
History: No changes posted
A study to investigate the effect of ASP1941 on the pharmacokinetics and safety of glimepiride (Part A) and to investigate the effect of glimepiride on the pharmacokinetics, safety and pharmacodynamics of ASP1941 (Part B).

Condition Intervention Phase
Healthy Subjects
Drug: ASP1941
Drug: Glimepiride
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Basic Science
Official Title: An Open-label, Randomized Crossover Study to Evaluate the Effect of ASP1941 on the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Glimepiride in Healthy Subjects and Vice Versa

Resource links provided by NLM:

Further study details as provided by Astellas Pharma Inc:

Primary Outcome Measures:
  • Effect of multiple doses of ASP1941 on the Pharmacokinetics of glimepiride [ Time Frame: 14 days ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Effect of multiple doses of glimepiride on the Pharmacokinetics of ASP1941 [ Time Frame: 14 days ] [ Designated as safety issue: No ]

Enrollment: 52
Study Start Date: December 2009
Study Completion Date: April 2010
Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: ASP1941
    Drug: Glimepiride
Detailed Description:
Study includes two parts. Part A is to investigate the effect of multiple oral doses of ASP1941 on the pharmacokinetics of glimepiride, and Part B is to investigate the effect of multiple oral doses of glimepiride on the pharmacokinetics of ASP1941.

Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • BMI between 18.5 and 30 kg/m2, inclusive

Exclusion Criteria:

  • Any of the liver function tests above the upper limit of normal
  • Pulse <40 or >90 bpm; Systolic Blood Pressure >140 mmHg; Diastolic Blood Pressure > 90 mmHg
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01302158

Groningen, Netherlands, 9470 AE
Sponsors and Collaborators
Astellas Pharma Inc
Study Director: Use Central Contact Astellas Pharma Europe B.V.
  More Information

Responsible Party: Disclosure Office Europe, Astellas Pharma Europe BV Identifier: NCT01302158     History of Changes
Other Study ID Numbers: 1941-CL-0059  2009-013172-50 
Study First Received: February 21, 2011
Last Updated: February 21, 2011
Health Authority: Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)

Keywords provided by Astellas Pharma Inc:
Drug-Drug interaction
Healthy subjects

Additional relevant MeSH terms:
Anti-Arrhythmia Agents
Hypoglycemic Agents
Physiological Effects of Drugs
Immunosuppressive Agents
Immunologic Factors processed this record on December 08, 2016